Postpartum affective disorder (AD), including postpartum depression (PPD), affects more than one in two hundred women with no history of prior psychiatric episodes, and raises the risk of later affective disorder for those women, according to a new study published in PLOS Medicine by Marie-Louise Rasmussen from Statens Serum Institut, Denmark, and colleagues.
PPD is estimated to affect more than 5 percent of all women following childbirth, making it the most common postnatal complication of childbearing. In the new study, researchers analyzed data from the Danish national registries on 457,317 women who had a first child (and subsequent births) between 1996 and 2013 and had no prior psychiatric hospital contacts or use of antidepressants. Postpartum AD was defined as an antidepressant prescription fill or hospital contact for depression within six months after birth.
In the Danish cohort, 0.6% of all childbirths among women with no history of psychiatric disease led to postpartum AD. A year after their first treatment, 27.9% of these women were still in treatment; after four years, that number was 5.4%. For women with a hospital contact for depression after a first birth, the risk of postpartum AD recurrence was 21%; the recurrence was 15% for women who took antidepressants after a first birth. These rates mean that, compared to women without history of AD, postpartum AD is 46 and 27 times higher in subsequent births for women with postpartum AD after their first birth.
"These population-based figures provide valuable guidance to physicians treating women with PPD," the authors say. "It underlines the seriousness of single initial episodes and highlights the necessity of both primary and secondary preventive measures of which several exist."
This work was funded by the Lundbeck Foundation , grant no. R54-A5685). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
I have read the journal's policy and the authors of this manuscript have the following competing interests: PV reports receiving payment for presentations from HB-pharma, AstraZeneca, Servier, and Boehringer Ingelheim (all more than 4 years ago).
Rasmussen M-LH, Strøm M, Wohlfahrt J, Videbech P, Melbye M (2017) Risk, treatment duration, and recurrence risk of postpartum affective disorder in women with no prior psychiatric history: A population-based cohort study. PLoS Med 14(9): e1002392. https://doi.org/10.1371/journal.pmed.1002392
Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
Center for Neuropsychiatric Depression Research, Mental Health Center Glostrup, Glostrup, Denmark
Department of Medicine, Stanford University School of Medicine, Stanford, California, United States of America
IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002392